Skip to main content

ImageneBio, Inc.

corporate_fare Company Profile

ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed IMA - Latest Insights

IMA
Apr 21, 2026, 4:00 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Omega Fund, including Director Stampacchia, invests $2.5M in ImageneBio PIPE
Sentiment: Positive
View Wiseek Article
IMA
Apr 16, 2026, 7:23 PM EDT
Filing Type: 4
Importance Score:
9
OrbiMed Advisors, a Director, Invests $3.75M in ImageneBio Private Placement
Sentiment: Positive
View Wiseek Article
IMA
Apr 13, 2026, 8:21 AM EDT
Filing Type: 424B3
Importance Score:
8
ImageneBio Registers 2.5M Common Shares for Resale by Investors from Recent $30M Private Placement
Sentiment: Negative
View Wiseek Article
IMA
Apr 13, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
ImageneBio Secures $30M in Private Placement of Pre-Funded Warrants for Clinical Development
Sentiment: Neutral
View Wiseek Article
IMA
Apr 13, 2026, 7:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
ImageneBio Secures $30M Private Placement, Bolstering Funds for Clinical Programs
Sentiment: Neutral
View Wiseek Article
IMA
Mar 10, 2026, 8:33 AM EDT
Filing Type: 10-K
Importance Score:
9
ImageneBio Reports Positive Clinical Data for Lead Asset IMG-007, Secures $75M PIPE Financing, and Notes Competitor Exit
Sentiment: Positive
View Wiseek Article
IMA
Mar 10, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
9
ImageneBio Secures Substantial Cash Runway of $135.3M, Reports Improved Full-Year EPS
Sentiment: Positive
View Wiseek Article
IMA
Mar 10, 2026, 8:06 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ImageneBio Cuts 2025 Loss Per Share by Over 50% to $9.64
Sentiment: Positive
View Wiseek Article